These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 184556)

  • 21. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiestrogen-induced remissions in stage IV breast cancer.
    Manni A; Trujillo J; Marshall JS; Pearson OH
    Cancer Treat Rep; 1976 Oct; 60(10):1445-50. PubMed ID: 1021225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Steroid receptors in breast cancer.
    Desombre ER
    Monogr Pathol; 1984; (25):149-74. PubMed ID: 6377047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bilateral adrenalectomy in selected patients with carcinoma of the breast.
    Singhakowinta A; Henderson MD; Vaitkevicius VK
    Surg Gynecol Obstet; 1974 May; 138(5):689-92. PubMed ID: 4362909
    [No Abstract]   [Full Text] [Related]  

  • 26. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer.
    Allegra JC; Lippman ME; Thompson EB; Simon R; Barlock A; Green L; Huff KK; Do HM; Aitken SC
    Cancer Res; 1979 May; 39(5):1447-54. PubMed ID: 427788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
    Klaassen DJ; Rapp EF; Hirte WE
    Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hormone receptor system].
    Kobayashi S
    Gan To Kagaku Ryoho; 1988 Dec; 15(12):3189-95. PubMed ID: 3196039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Steroid hormone receptors in human breast cancer and clinical correlations.
    Maass H; Engel B; Nowakowski H; Stolzenbach G; Trams G
    Arch Geschwulstforsch; 1975; 45(5):423-9. PubMed ID: 174516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current status of estrogen receptors in human breast cancer.
    McGuire WL
    Cancer; 1975 Aug; 36(2):638-44. PubMed ID: 168960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A re-evaluation of the place of major extirpation in the management of patients with metastatic mammary carcinoma.
    Delarue NC; Peters V; Anderson WS; Starr J
    Can Med Assoc J; 1967 Mar; 96(11):637-51. PubMed ID: 4289692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized sequential hormonal therapy vs adrenalectomy for metastatic breast carcinoma.
    Yonemoto RH; Tan MS; Byron RL; Riihimaki DU; Keating J; Jacobs W
    Cancer; 1977 Feb; 39(2):547-55. PubMed ID: 319892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ablative procedures in patients with metastatic breast carcinoma.
    Wells SA; Santen RJ
    Cancer; 1984 Feb; 53(3 Suppl):762-5. PubMed ID: 6362827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogen receptor and natural course of breast cancer.
    Singhakowinta A; Potter HG; Buroker TR; Samal B; Brooks SC; Vaitkevicius VK
    Ann Surg; 1976 Jan; 183(1):84-8. PubMed ID: 174500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LevoDopa test and estrogen receptor assay in prognosticating responses of patients with advanced cancer of the breast to endocrine therapy.
    Sasaki GH; Leung BS; Fletcher WS
    Ann Surg; 1976 Apr; 183(4):392-6. PubMed ID: 178277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current cancer concepts. Comment: the basis for selection of hormonal addition or subtraction.
    Rubin P
    JAMA; 1967 Jun; 200(11):977-8. PubMed ID: 6071641
    [No Abstract]   [Full Text] [Related]  

  • 39. The thermoprofile as an early indicator of breast cancer response to hormonal therapy.
    Stoll BA
    Cancer; 1971 Jun; 27(6):1379-83. PubMed ID: 4325984
    [No Abstract]   [Full Text] [Related]  

  • 40. Vaginal cytology as an aid to hormone therapy in postmenopausal cancer of the breast.
    Stoll BA
    Cancer; 1967 Oct; 20(10):1807-13. PubMed ID: 4168341
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.